Pulmonx said today data from the Stelvio trial of its Chartis system and Zephyr endobronchial valve demonstrated statistically and clinically significant outcomes in lung function, exercise capacity and quality of life in severe emphysema patients. Data from the study was published today in the New England Journal of Medicine. “When we select patients with the […]
Pulmonx said earlier this month that a sham-controlled trial of its Zephyr endobronchial valve met and exceeded its primary endpoints, reporting a 20.9% average improvement in lung function. The Believer-Hifi study, published in The Lancet, is the 1st successful sham-controlled trial of any invasive emphysema device, Redwood City, Calif.-based Pulmonx said. “We have been able […]
Pulmonx said yesterday that it named Glen French, the co-founder and CEO of Asthmatx who led it to an acquisition by BSX, to be its new president and chief executive.
Lung treatment company Pulmonx won FDA approval to begin pivotal clinical trials of its Zephyr Endobronchial Valve in treating patients with emphysema.
The minimally invasive Zephyr device is a one-way bronchial valve designed to reduce volume in diseased areas of the lungs, allowing healthier areas to work better. It’s implanted bronchoscopically and can be removed later if necessary, according to a press release.